Thrombotic microangiopathy in a 17-year-old patient: TTP, HUS or a bit of both?

Clinical Nephrology

Volumn 68, Issue 6, 2007, Pages 405-411

  Gerth, J ^a   Busch, M ^a   Oyen, F ^b   Schneppenheim, R ^b   Keller, T ^c   Budde, U ^d   Groene, H J ^e   Wolf, Gunter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HELIOS KLINIKUM ERFURT   (Germany)

^d Arndt and Partner   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

ADAMTS13; Hemolytic uremic syndrome; Plasmapheresis; Thrombotic microangiopathies; Thrombotic thrombocytopenic purpura; Verotoxin

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CIPROFLOXACIN; CREATININE; IMIPENEM; METHYLPREDNISOLONE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; VEROTOXIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ANTIBODY DETECTION; ARTICLE; ASCITES; BACKACHE; BACTERIUM DETECTION; BACTERIUM ISOLATION; BACTERIURIA; BRAIN HEMORRHAGE; CASE REPORT; CHILL; CREATININE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEVER; FLANK PAIN; GENE SEQUENCE; GRAND MAL SEIZURE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; LABORATORY TEST; LEUKOCYTURIA; MALE; PERIPHERAL EDEMA; PLASMAPHERESIS; PLEURA EFFUSION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SEROTYPE; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; THROMBOCYTE TRANSFUSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINARY TRACT INFECTION;

EID: 37149037950     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68405     Document Type: Article

References (30)

1. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage ofthe endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004; 104: 100-106.
2. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 2006; 70: 423-431.
3. Coppo P, Adrie C, Azoulay E, Leleu G, Oksenhendler E, Galicier L, Le Gall JR, Bussel A, Schlemmer B. Infectious diseases as a trigger in thrombotic microangiopathies in intensive care unit (ICU) patients? Intens Care Med. 2003; 29: 564-569.
4. Crawley JTB, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 2005; 105: 1085-1093.
5. Dong JF. Structural and functional correlation of ADAMTS13. Curr Opin Hematol. 2007; 14: 270-276.
6. Furlan M, Robles R, Galbusera M Remuzzi G, Kyrie PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339: 1578-1584.
7. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996; 87: 4223-4234.
8. George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2003; 10: 339-344.
9. George JN. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clin Adv Hematol Oncol. 2005; 3: 627-632.
10. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients 1997-2000, in Germany and Austria: a prospective study. J Infect Dis. 2002; 186: 493-500.
11. Groot E, de Groot PG, Fijnheer R, Lenting PJ. The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol. 2007; 14: 284-289.
12. Kaikita K, Soejuna K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMST13) activity in acute myocardial infarction. J Thromb Hameost. 2006; 4: 2490-2493.
13. Kavanagh G, Goodship TH, Richards A. Atypical hemolytic uraemic syndrome. Br Med Bull. 2006; 77: 5-22.
14. Lattuada A, Rossi E, Calzarossa C, CandobCi R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica. 2003; 88: 1029-1034.
15. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982; 307: 1432-1435.
16. Moore JC, Hayward CPM, Warkentin TE, Kelton JG. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood. 2001; 98: 1842-1846.
17. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D. Shiga toxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005; 115: 2752-2761.
18. Naqvi TA, Baumann MA, Chang JC. Postoperative thrombotic thrombocytopenic purpura: a review. Int J Clin Pract. 2004; 58: 169-172.
19. Nguyen TC, Liu A, Liu L, Ball C, Choi H, May WS, Alboulfatova K, Bergeron AL, Dong JF. Acquired ADAMTS13 deficiency in pediatric patients with severe sepsis. Hematologica. 2007; 92: 121-124.
20. Starke RM Machin S, Scully M, Purdy G, Mackie I. The clincial utility of ADMTS13 activity, antigen and auto-antibody assays in thrombotic thrombocytopenic purpura. Br J Haernatol. 2006; 136: 649-655.
21. Tarr PI, Gordon CA, Chandler WL. Shiga toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005; 365: 1073-1086.
22. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996; 87: 4235-4244.
23. Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int. 2006; 70: 16-23.
24. Tsai HM, Chandler WL, Sarode R, Hoffman R, Jelacic S, Habeeb RL, Watkins SL, Wong CS, Williams GD, Tarr PI. Von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res. 2001; 49: 653-659.
25. Tsai HM, Lion EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339: 1585-1594.
26. Verweyen HM, Karch H, Allerberger F, Zimmerhackl LB. Enterohemorrhagic Escheria coli (EHEC) in pediatric hemolytic-uremic syndrome: a prospective study in Germany and Austria. Infection. 1999; 27: 341-347.
27. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003; 102: 60-68.
28. Vesely SK, Li X, McMinn JR, Terrell DR, George JN. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion. 2004; 44: 1149-1158.
29. Veyradler A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001; 98: 1765-1772.
30. Wolf G. Not known from ADAM(TS-13)-novel insights into the pathophysiology of thrombotic microangiopathies. Nephrol Dial Transplant. 2004; 19: 1687-1693.